The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
IP: Use at 2-5 µg/mg of lysate.
WB: 1/2000 - 1/10000. Predicted molecular weight: 142 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
GTPase activator for the Rho-type GTPases by converting them to an inactive GDP-bound state. Has strong activity toward RHOA, and weaker activity toward RAC1 and CDC42. May act as a specific effector of RAP2A to regulate Rho. In concert with RASIP1, suppresses RhoA signaling and dampens ROCK and MYH9 activities in endothelial cells and plays an essential role in blood vessel tubulogenesis.
Widely expressed. Highly expressed in skeletal muscle and heart. Expressed at intermediate level in placenta, liver and pancreas. Weakly expressed in brain, lung and kidney.
Rho GTPase activating protein 29 isoform CRA_a antibody
Rho GTPase activating protein 29 isoform CRA_b antibody
Rho GTPase-activating protein 29 antibody
Rho-type GTPase-activating protein 29 antibody
Anti-Rho GTPase activating protein 29 antibody images
Western blot - Rho GTPase activating protein 29 antibody (ab85853)
All lanes : Anti-Rho GTPase activating protein 29 antibody (ab85853) at 0.4 µg/ml
Lane 1 : HeLa whole cell lysate at 50 µg Lane 2 : HeLa whole cell lysate at 15 µg Lane 3 : HeLa whole cell lysate at 5 µg Lane 4 : 293T whole cell lysate at 50 µg Lane 5 : NIH3T3 whole cell lysate at 50 µg
Immunoprecipitation - Rho GTPase activating protein 29 antibody (ab85853)
Detection of Rho GTPase activating protein 29 by Western Blot of Immunprecipitate.
ab85853, at 1 µg/ml, staining Rho GTPase activating protein 29 in HeLa whole cell lysate immunoprecipitated using ab85853 at 3µg/mg lysate (1 mg/IP; 20% of IP loaded/lane). Detection: Chemiluminescence with exposure time of 10 seconds.